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Objective Hepatitis E virus (HEV) infection can take
chronic courses in immunocompromised patients
potentially leading to liver cirrhosis and liver failure.
Ribavirin (RBV) is currently the only treatment option for
many patients, but treatment failure can occur which has
been associated with the appearance of a distinct HEV
polymerase mutant (G1634R). Here, we performed a
detailed analysis of HEV viral intrahost evolution during
chronic hepatitis E infections.
Design Illumina deep sequencing was performed for
the detection of intrahost variation in the HEV genome
of chronically infected patients. Novel polymerase
mutants were investigated in vitro using state-of-the-art
HEV cell culture models.
Results Together, these data revealed that (1) viral
diversity differed markedly between patients but did not
show major intraindividual short-term variations in
untreated patients with chronic hepatitis E, (2) RBV
therapy was associated with an increase in viral
heterogeneity which was reversible when treatment was
stopped, (3) the G1634R mutant was detectable as a
minor population prior to therapy in patients who
subsequently failed to achieve a sustained virological
response to RBV therapy and (4) in addition to G1634R
further dominant variants in the polymerase region
emerged, impacting HEV replication efficiency in vitro.
Conclusions In summary, this first investigation of
intrahost HEV population evolution indicates that RBV
causes HEV mutagenesis in treated patients and that an
emergence of distinct mutants within the viral
population occurs during RBV therapy. We also suggest
that next-generation sequencing could be useful to guide
personalised antiviral strategies.
INTRODUCTION
Hepatitis E virus (HEV) is a non-enveloped single-
stranded RNA virus and a common cause of acute
hepatitis worldwide.1 2 More than 3 million symp-
tomatic hepatitis E cases occur each year accounting
for an estimated 70 000 deaths.1 Four different
HEV genotypes infecting humans have been
described. HEV genotypes 1 and 2 have been
linked with water-borne outbreaks in low/
middle-income countries and exclusively infect
humans. In contrast, HEV genotypes 3 and 4 can
be found in various animal species, with the major
route of HEV transmission to humans via
Significance of this study
What is already known on this subject?
▸ RNA viruses like hepatitis E virus (HEV)
establish populations with high intrahost
variability, which enables them to rapidly adapt
to changing immune responses.
▸ HEV is the major cause of acute hepatitis, but
can also establish chronic infections in
immunocompromised patients. Ribavirin (RBV)
is currently the only treatment option available.
▸ RBV inhibits HEV replication in vitro by, among
other mechanisms, increasing the error rate of
the viral RNA-dependent RNA polymerase.
A mutation (G1634R) in the polymerase region
of HEV can lead to treatment failure during
RBV therapy.
What are the new findings?
▸ Viral diversity differed markedly between
patients but did not show major intraindividual
short-term variations in untreated patients with
chronic hepatitis E.
▸ RBV therapy was associated with an increase in
viral heterogeneity in all open-reading frames,
which was reversible when treatment was
stopped.
▸ The G1634R mutant was detectable as a minor
population prior to therapy in patients who
subsequently failed to achieve a sustained
virological response to RBV therapy.
▸ Additional dominant variants in the polymerase
emerged during RBV therapy impacting HEV
replication efficiency in vitro.
How might it impact on clinical practice in
the foreseeable future?
▸ Investigation of HEV intrahost population
evolution indicates that RBV causes HEV
mutagenesis in treated patients and that an
emergence of distinct viral populations may
occur during RBV therapy.
▸ Next-generation sequencing methods could be
diagnostically used to rapidly identify patients
at risk for treatment failure and predict therapy
outcomes of chronically infected patients in
clinics and could be a useful tool for
personalised antiviral strategies.
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consumption of undercooked meat.1 3 4 It is now well estab-
lished that prolonged HEV viraemia and even courses of
chronic hepatitis E may occur in immunocompromised patients
potentially leading to liver cirrhosis and liver failure.5 6
Pathogenesis, epidemiology and evolution of RNA viruses are
influenced by the composition of the viral population.7 Genetic
diversity is achieved by high mutation rates and as a conse-
quence, quasi-species populations are generated which may
allow adaptation to antiviral drugs, potentially inducing resist-
ance or enhanced viral fitness.8 In addition, viral diversity repre-
sents a potential mechanism to escape a successful immune
response while in turn immune pressure may drive viral evolu-
tion.9 For HEV, greater intrahost heterogeneity has been linked
with evolution to chronicity.10 The immune pressure on HEV
maybe weak in chronic hepatitis E where HEV-specific T-cell
responses are barely detectable, but various cytokines and che-
mokines are elevated in acute and chronic hepatitis E correlating
with disease activity and progression of liver disease.10 11
However, the mode and tempo of HEV evolution in persistently
infected patients undergoing therapy is currently unknown.
Ribavirin (RBV) monotherapy is currently considered as the
treatment of choice for patients with chronic hepatitis E.12 13
While the majority of patients clear HEV, after 3–5 months of
RBV therapy cases of on-treatment failures or post-treatment
relapses have been reported.14–16 Recently, the selection of a dis-
tinct HEV mutant in the C-terminal region of the HEV poly-
merase (G1634R) during RBV therapy was reported. The
G1634R mutant was still sensitive to RBV but conferred an
enhanced replication fitness to the virus in vitro.17 Consequently,
the selection of the G1634R mutant likely contributed to treat-
ment failure. It is currently unknown if a minor part of the viral
population harboured this particular mutation prior to therapy
commencement.
RBV inhibits HEV replication in vitro by a depletion of cellu-
lar GTP pools.18 Additional modes of actions of RBV might be
important in patients as inosine-50-monophosphate dehydrogen-
ase (IMPDH) inhibition by mycophenolic acid does not always
prevent chronicity in HEV-infected solid organ transplant
(SOT) recipients.6 Intrahost populations of RNA viruses are
believed to exist at the edge of a genomic error threshold, and
exceeding the threshold by RBV-induced additional mutations
could lead to a sequence of error catastrophes resulting in viral
extinction.19 20 Here, we hypothesised that RBV-induced
increased mutagenesis may be implicated in HEV treatment out-
comes as has been shown for various other viruses.21
The aims of the current study were to investigate HEV
genome evolution in all open-reading frames (ORFs) prior to
and during RBV therapy in patients with chronic hepatitis by
Illumina deep sequencing. Furthermore, we wanted to deter-
mine if the G1634R mutant was present already before therapy
as a minor population in patients not achieving a sustained viro-
logical response to RBV therapy. Finally, we aimed to explore if
additional amino acid changes were selected during therapy and
if these mutations had an impact on HEV replication in vitro.
SUBJECTS, MATERIALS AND METHODS
Study subjects
All patients were recruited at Hannover Medical School
between 2008 and 2015. Overall, 12 patients with chronic
hepatitis E were included, for whom at least 2 stored plasma
samples with detectable HEV RNA were available. In addition,
for RBV-treated patients, we aimed to study at least one vir-
aemic sample during treatment and in patients not achieving a
sustained virological response, a post-treatment HEV
RNA-positive sample was required to be available. RBV was
administered orally twice daily with an initial daily dose of
600–1000 mg, depending on the patients’ haemoglobin level
and comorbidities, as previously described.15 Dose reductions
were performed if haemoglobin levels declined and/or patients
developed symptoms associated with anaemia. At each visit,
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), γ-glutamyltranspeptidase (GGT) and HEV RNA viraemia
were determined. Anti-HEV status was determined using Wantai
HEV IgG ELISA (Beijing, China). The study protocol was in
line with the ethical guidelines of the Institutional Review
Committee. The study was approved by the ethics committee of
Hannover Medical School in Hannover, Germany (record 930–
2011), and it conforms to the ethical guidelines of the 1975
Declaration of Helsinki. All patients gave written informed
consent to participate in this study. Healthy volunteers were
also recruited from Hannover Medical School.
Cell culture
Human Huh7.5 hepatoma cells (kindly provided by Professor
Charles Rice) were kept in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen, Karlsruhe, Germany) supplemented with
10% fetal bovine serum (FBS; Invitrogen), 1% non-essential
amino acids (Invitrogen), 100 mg/mL of streptomycin (Invitrogen)
and 100 IU/mL of penicillin. Cells were kept at 37°C in a 5% (v/v)
CO2 incubator.
HEV constructs, cloning and in vitro transcription
A plasmid construct containing a subgenomic HEV Kernow-C1
p6 clone (GenBank Accession Number: JQ679013) sequence
coupled with a Gaussia luciferase reporter gene (p6-Gluc) was
used to generate HEV in vitro transcripts as previously described
with an additional capping step (m7G Cap Analog, Promega,
Madison, Wisconsin, USA).22 23 Single-nucleotide variations were
introduced using site-directed mutagenesis PCR or gBlocks Gene
Fragments (IDT, Coralville, Iowa, USA) (detailed information and
primer sequences available on request).
HEV replication assay
HEV subgenomic RNAs were transfected into cells via electro-
poration as previously described.24 In brief, 5×106 cells/mL
Huh7.5 cells in 400 mL Cytomix containing 2 mM ATP and
5 mM glutathione were mixed with 3 mg of p6-Luc subgenomic
HEV RNA. Electroporation was carried out with a Gene Pulser
system (Bio-Rad, Munich, Germany). Cells were immediately
transferred to 12.1 mL of DMEM complete, and 50 mL contain-
ing 2×104 cells/well was seeded onto 96-well plates. After 4 h,
50 mL DMEM complete containing RBV at indicated concentra-
tions, or DMEM complete only, was added. Viral replication
was determined by measuring luciferase activity in the super-
natant of 96-well plates 72 h after transfection.
Luciferase reporter assay
HEV subgenomic replicon (SGR) replication was assessed as
described before.25 In brief, 20 mL of supernatant was added
per well of a 96-well white, flat-bottom microplate followed by
the detection of luminescence for HEV encoding Gaussia luci-
ferase using a microplate reader (CentroXS3 LB960, Berthold
Technologies, Bad Wildbad, Germany) using coelenterazine as a
substrate.
Statistics
Data were analysed using GraphPad Prism V.6.0b (GraphPad
Software, La Jolla, California, USA). Comparisons of single-
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nucleotide variants (SNV; a single-nucleotide variation among an
individual) between RBV-treated patients and patients who did
not receive RBV were performed using Mann–Whitney U test.
p Values of <0.05 were considered to be significant (*p<0.05;
**p<0.01; ***p<0.001 or ****p<0.0001). GraphPad Prism 5
software was used for dose–response curve calculation.
RESULTS
Patient characteristics
We studied 12 selected patients with chronic HEV genotype 3
infections (8 patients with genotype 3c, 3 patients with geno-
type 3f and 1 patient with genotype 3e). The median age of the
patient cohort was 46 years (range 14–70 years) and eight
patients were male. Eleven of the 12 patients were organ trans-
plant recipients (table 1). Three patients cleared HEV after
reduction of immunosuppressive medication while antiviral
therapy with RBV was initiated in nine subjects. RBV treatment
was successful in five patients and failed in four organ transplant
recipients (patient # 1–4). Initial immunosuppressive medica-
tions are listed in table 1 and included corticosteroids, prolifer-
ation inhibitors, calcineurin inhibitors and mechanistic Target of
Rapamycin (mTOR) inhibitors. Immunosuppressive regimens
were adjusted over time depending on the clinical parameters of
the patients.
Evolution of HEV intrahost populations in patients with
chronic hepatitis E
RNA viruses exist as a diverse population of genetically related
but distinct variants. For HEV, viral heterogeneity determined at
a single time point has been associated with the outcome of
infection.10 We here first performed an analysis of intrahost
HEV viral population evolution by Illumina deep sequencing of
the HEV ORF1 region encoding for the RNA-dependent RNA
polymerase (RdRp) of at least two time points in patients not
receiving antiviral treatment with RBV (figure 1). Significant
interindividual variability of both synonymous (silent) as well as
non-synonymous (amino acid replacement) SNVs was evident
(figure 1). However, within a given patient (#1, #4, #8, #9,
#10, #11), the HEV population composition was rather stable
over several weeks or even months for the majority of patients
before on-set of RBV treatment as well as in patients who never
received antiviral therapy.
Effect of RBV on the heterogeneity in the HEV ORF1
encoding for the RNA-dependent RNA polymerase
To ascertain whether RBV therapy has as an influence on viral
heterogeneity, we compared differences in the number of sites
exhibiting non-synonymous and synonymous SNVs between
RBV-treated and non-treated patients with chronic hepatitis E
via next-generation sequencing methods. Indeed, patients receiv-
ing RBV showed higher frequencies of both synonymous (figure
2A) and non-synonymous (figure 2B) SNVs compared with
samples drawn when patients were untreated. This finding indi-
cates that RBV therapy leads to an increased nucleotide substitu-
tion rate in patients with HEV. We next analysed the long-term
evolution of the total number of synonymous and non-
synonymous SNV in three patients not achieving a sustained
virological response (patients #1, #2 and #4). For these
patients, samples were available before, during and after RBV
medication (figure 3). HEV RNA copy numbers during the
course of infection ranged for patient #1 from 5.6×105 to
1.09×107, for patient #2 from 1.66×104 to 1.2×107 and for
patient #4 from 1.54×104 to 6.75×108 RNA copies/mL,
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synonymous and non-synonymous SNVs during RBV medica-
tion with higher changes in the number of sites exhibiting sub-
stitutions for synonymous SNV (figure 3). In patient #1, a
marked SNV decline appeared after RBV was stopped and in
patient #2 a gradual decline became evident 3–6 months after
treatment for both, synonymous as well as non-synonymous
SNV (figure 3A, B). Patient #4 showed a marked increase in
SNVs in particular during a second course of RBV therapy;
however, no post-treatment samples were available in this case
(figure 3C). In all three patients, the occurrence of nucleotide
substitutions was mainly caused by transitions, that is, a purine–
purine or pyrimidine–pyrimidine exchange, and only to a lesser
extent due to nucleotide transversions (purine–pyrimidine or
pyrimidine–purine substitution, figure 3A–C). In summary, the
analysis of viral evolution during and after therapy in individual
patients shows that increasing SNVs over time correlate with con-
tinued administration of RBV. Furthermore, RBV-induced muta-
genesis seemed to be reversible when treatment was stopped.
Time course of distinct non-synonymous SNVs in patients
not achieving a sustained virological response
to RBV therapy
We next analysed, if viral heterogeneity and detection of the
G1634R mutant via deep sequencing would be predictive for
Figure 1 Changes in total number of sites exhibiting variations in the hepatitis E virus (HEV) open-reading frame 1 (ORF1) region without the
influence of ribavirin (RBV) in chronically infected HEV patients over time. The time course of the appearance of non-synonymous (black lines) and
synonymous (grey lines) single-nucleotide variations (SNVs) in six chronically infected patients included in the study is depicted.
Figure 2 Effect of ribavirin (RBV) on the heterogeneity of hepatitis E virus (HEV) open-reading frame 1 (ORF1) region in the viral intrahost
population in chronically infected patients. The total numbers of nucleotide sites exhibiting synonymous (A) as well as non-synonymous (B)
single-nucleotide variations (SNVs) identified in the hepatitis E viral intrahost population in solid organ transplant patients are compared. Open
circles represent analyses of available samples of patients before receiving RBV or before and during other antiviral treatment. Black dots show the
number of SNVs in HEV ORF1 identified in patients during RBV treatment. Horizontal bars indicate the median, significance was tested with the
Mann–Whitney U test (***p<0.001; ****p<0.0001).
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subsequent responses to RBV treatment. There was no signifi-
cant difference between the numbers of synonymous and non-
synonymous SNVs detected in responding patients and patients
not achieving a sustained virological response to RBV therapy
(see online supplementary figure S1). In most patients who
cleared the HEV infection, the G1634R mutation could not be
identified or was present at very low levels in the viral popula-
tion. In two patients, the arginine at position 1634 was already
the dominant strain from the beginning onwards. However, the
G1634R mutant that has been selected during therapy in
patients with treatment failure was detectable as minor popula-
tion before therapy in patient #1 and patient #2 (figure 4).
Deep sequencing revealed a gradual increase in the G1634R
variant with continued RBV therapy until month 11, where it
comprises more than two thirds of the HEV population (figure
4A). In patient #2, the G1634R variant also gradually increased
with progression of RBV therapy until the ninth month (figure
4B). Of note, the relative dominance of G1634R declined
around 3 months after RBV medication was stopped and
decreased to one-third of the population (figure 4B). G1634R
was the dominant strain in patient #3 already before therapy
which did not change during treatment (data not shown), while
in patient #4 the G1634R variant was only detectable in the
population at month 11 and only at as very low frequency of
about 3.4% (data not shown). Thus, the overall HEV heterogen-
eity does not seem to be associated with response to RBV
Figure 3 Course of number of sites
exhibiting nucleotide substitutions over
time in three chronically hepatitis E
virus (HEV) infected solid organ
transplant recipients experiencing
ribavirin (RBV) treatment failure.
Shown are the total numbers of
synonymous (solid black lines) and
non-synonymous (dashed black lines)
single-nucleotide variations (SNVs), as
well as the numbers of nucleotide
transitions (solid grey lines) and
transversions (dashed grey lines) in the
HEV open-reading frame 1 (ORF1)
identified in three chronically infected
patients (A, patient #1; B, patient #2;
C, patient #4). Black bars indicate
duration of RBV treatment starting
with the first RBV dose at month 0.
Todt D, et al. Gut 2016;0:1–11. doi:10.1136/gutjnl-2015-311000 5
Hepatology
Figure 4 Time course of
non-synonymous single-nucleotide
variations at certain positions of the
hepatitis E virus (HEV) open-reading
frame 1 (ORF1) in patient samples.
Changes in nucleotide frequencies
(x-axes) resulting in alterations of the
predominant amino acids over
monitoring time (y-axes) of chronically
infected patients are depicted at amino
acid positions indicated above the
plots. The altered nucleotides in the
coding triplets are underlined. White
bars indicate proportions of adenine,
light grey bars indicate proportions of
guanine, dark grey bars represent
cytosine and black bars show amount
of thymine. (A) Three positions with a
change in the dominant amino acid
were identified for patient #1, four
non-synonymous SNVs were found in
patient #2 (B) and four in patient #4
(C). Black vertical lines indicate course
of administration of ribavirin (RBV).
Figure 5 Ribavirin (RBV) sensitivity and replication fitness of hepatitis E virus (HEV) subgenomic replicon SGR wild-type (wt) and mutants
harbouring the single-nucleotide variations identified in patients experiencing RBV treatment failure. (A) Antiviral activity of RBV against HEVp6 wt
replicon (solid line, EC50=13.61 mM, 95% CI 12.35 to 15.00), the G1634R mutant (dashed line, EC50=12.9 mM, 95% CI 11.91 to 13.98), the
K1383N/Y1587F/G1634R mutant (dotted line, EC50=4.95 mM, 95% CI 4.47 to 5.49), the K1383N/D1384G/K1398R/Y1587F mutant (dotdashed line,
EC50=11.98 mM, 95% CI 10.39 to 13.82) and the K1383N/D1384G/V1479I/G1634R mutant (dotdotdashed line, EC50=3.03 mM, 95% CI 2.80 to
3.28) replicons in Huh7.5. (B) Luminescence read-out of Huh7.5 cells transfected with the five constructs 72 h post-transfection. As a control for
replication-specific read-out, the wt replicon was treated with 62.5 mM RBV.
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therapy. However, variants possibly being associated with treat-
ment failure may already be detectable before antiviral therapy
as minor populations.
In addition to G1634R, two further mutations (K1383N and
Y1587F) appeared in patient #1 in the C-terminal region of the
HEV ORF1 at month 5 of therapy (figure 4A). The variant
Y1587F did not exist and variant K1383N was present at
extremely low frequencies prior to initiation of RBV medication
(figure 4A). For the second non-responder (patient #2), we also
found three additional amino acid changes in the HEV polymer-
ase over time (K1383N, D1384G and V1479I; figure 4B).
Similar to G1634R, the selection of these variants was reversible
when RBV was stopped. Figure 4C shows the time course of
SNV of the only non-responder not harbouring the G1634R
(patient #4). In patient #4, we observed three amino acid
changes previously detected in patient #1 (K1383N and
Y1587F) and patient #2 (K1383N and D1384G). Additionally,
one variant (K1398R) was identified which was not detectable
in the other patients (figure 4). A linkage analysis using clonal
sequencing methods employing amplicons obtained from time
points with highest viral heterogeneity revealed different combi-
nations of the identified variations on individual viral genomes
(see online supplementary figure S2) that were present at differ-
ent frequencies. In viral populations of all three patients, the
wild-type sequences were no longer detectable anymore. For
patient #1, viral genomes harbouring all three mutations could
be detected (see online supplementary figure S2A), whereas for
patient #2 and patient #4 several combinations of mutations
were detected, but no viral genomes containing all four amino
acid changes (see online supplementary figure S2B, C). In
summary, the G1634R mutation was already detectable as a
minor variant prior to therapy and became dominant during
RBV administration. Furthermore, additional amino acid
changes in ORF1 could be identified that emerged in various
combinations in the viral population.
RBV sensitivity and viral replication of HEV subgenomic
replicon harbouring identified SNVs
In our previous study, it was demonstrated that the G1634R
mutant was still sensitive to RBV but conferred an enhanced
replication fitness to the virus in vitro.17 Here, we first con-
firmed that the previously described G1634R mutant
(EC50=12. 9 mM, 95% CI 11.91 to 13.98) introduced into a
genotype 3 replicon has comparable RBV sensitivity to the
HEVp6 wild-type (wt) replicon (EC50=13.61 mM, 95% CI
12.35 to 15.00) (figure 5A). However, the G1634R mutation
resulted in an increase in luminescence signal compared with
the wild-type construct suggesting increased viral RNA replica-
tion (figure 5B). RBV was further used as control for active viral
RNA replication in this assay setup. Consequently, after reveal-
ing two additional dominant amino acid changes close to the
G1634R site in patient #1 using deep sequencing, we also
introduced all three mutations (K1383N/Y1587F/G1634R) into
the HEVp6 replicon to investigate the RBV sensitivity and viral
replication compared with the HEVp6 wild-type replicon and
HEVp6 G1634R replicon. Interestingly, the K1383N/Y1587F/
G1634R combination showed an increased sensitivity to RBV
when compared with the wild-type or G1634R mutant
(EC50=4.95 mM, 95% CI 4.47 to 5.49) (figure 5A). Similar
viral replication could be detected for the K1383N/Y1587F/
G1634R construct compared with the wild-type construct after
transfecting Huh7.5 cells (figure 5B). A comparable phenotype
Figure 6 Effect of ribavirin (RBV) on the heterogeneity of hepatitis E virus (HEV) open-reading frame 2 (ORF2) and ORF3 in the viral intrahost
population in chronically infected patients experiencing RBV treatment failure. The total numbers of sites exhibiting synonymous (A and C) as well
as non-synonymous (B and D) single-nucleotide variations (SNVs) identified in ORF2 (A and B) and ORF3 (C and D) of the hepatitis E viral intrahost
population found in patient #1, patient #2 and patient #4 at time points of available serum samples before (open circles) and during RBV treatment
(black dots) are compared. Horizontal bars indicate the median, significance was tested with the Mann–Whitney U test (*p<0.05; **p<0.01).
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could be observed for the mutations found in patient #2
(K1383N/D1384G/V1479I/G1634R, EC50=3.03 mM, 95% CI
2.80 to 3.28), whereas a HEV construct harbouring the muta-
tions identified in patient #4 (K1383N/D1384G/K1398R/
Y1587F, EC50=11.98 mM, 95% CI 10.39 to 13.82) showed
replication levels as well as RBV sensitivity like the wild-type
replicon (figure 5A, B). In summary, next to the G1634R add-
itional ORF1 mutations could be identified that abrogated the
improved replication fitness and showed an increased RBV
sensitivity.
Effect of RBV on the heterogeneity of HEV in ORF2 and
ORF3 genome regions
To extend the RBV-induced mutagenesis analysis to HEV
genome regions other than the RdRp in ORF1, we next per-
formed deep-sequencing approach of ORF2 and ORF3 regions
with RBV-treated and non-treated patients with chronic hepatitis
E (figure 6). In line with the findings made for ORF1, patients
receiving RBV showed higher numbers of sites exhibiting both
non-synonymous (figure 6A, C) and synonymous (figure 6B, D)
in ORF2 and ORF3, respectively. The long-term evolution of
the total number of SNVs in ORF2 and ORF3 for the three
patients not receiving a sustained virological response demon-
strated an increase in SNVs over time which also correlated with
the administration of RBV and findings made for ORF1
(figure 7; compare figure 3). As the amplicon size for each ORF
reference was different, we performed a normalised comparison
of the number of sites exhibiting SNVs as well as average fre-
quencies of SNVs in percent between ORF1, 2 and 3 (see
online supplementary figure S3A–D). These results show that in
all genome regions comparable mutagenic effects of RBV can be
observed. Only the average frequencies of synonymous substitu-
tions in ORF1 under RBV treatment were not significantly
increased compared with the non-treated patient samples (see
online supplementary figure S3C). Monitoring the changes in
nucleotide frequencies in ORF2 and ORF3 resulting in
Figure 7 Course of number of sites exhibiting nucleotide substitutions over time in three chronically hepatitis E virus (HEV) infected solid organ
transplant recipients experiencing ribavirin (RBV) treatment failure. Shown are the total numbers of synonymous (solid black lines) and
non-synonymous (dashed black lines) single-nucleotide variations (SNVs), as well as the numbers of nucleotide transitions (solid grey lines) and
transversions (dashed grey lines) in the HEV ORF2 (left panels) and ORF3 (right panels) identified in three chronically infected patients not achieving
a sustained virological response (A, patient #1; B, patient #2; C, patient #4). Black bars indicate duration of RBV treatment starting with the first
RBV dose at month 0.
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alterations of the predominant amino acid over time in the
three chronically infected patients identified four mutations in
the ORF2 for patient #2 (P25S, G71R, P95S and V245I) and
patient #4 (G38S, A64T, P79S and T324S) and additionally
one mutation in the ORF3 of patient #4 (S82N) (see online
supplementary figure S4). In summary, in line with the results
described for ORF1, the increase of SNVs in individual patients
receiving RBV could also be observed in the HEV ORF2 and
ORF3.
DISCUSSION
Chronic hepatitis E is an increasing problem in immunocom-
promised patients, with RBV being the only treatment option in
many cases. Recently, the emergence of a distinct HEV polymer-
ase mutation (G1634R) during RBV therapy of chronic HEV
was reported demonstrating enhanced replication dynamics,
which likely contributed to treatment failure and a poor clinical
long-term outcome.17 In that study, selection of the
HEV-G1634R mutant was identified by standard population
sequencing. Here, we performed a detailed analysis of intrahost
HEV viral population evolution via deep sequencing of the
HEV genome in a larger cohort of patients at multiple time
points. We show that (1) the HEV population composition was
stable over several weeks or even months in most patients with
chronic HEV although it was variable between patients, (2) RBV
therapy was associated with a marked increase in viral popula-
tion heterogeneity and (3) in addition to G1634R further
mutants comprising the majority of the viral population
emerged during RBV therapy, which impacted HEV replication
efficiency.
HEV generally causes acute infections with rather short dura-
tions of viraemia in infected hosts. Prolonged courses of HEV
infections or even chronicity only occur with the introduction
of immunosuppressive medical therapies. Yet, the evolution of
the HEV population during prolonged viraemia has never been
previously studied. The potential importance of HEV hetero-
geneity for both development of chronic infections as well as
fibrosis progression has been suggested previously in an elegant
study from Toulouse.10 In line with that study, we here also
observed extensive variability in the complexity of the HEV
population between different patients. However, HEV diversity
remained rather stable within a given patient followed for
several months. This observation indicates a low level of
immune pressure in these patients with different types of
immunosuppressive medications. This is in agreement with our
earlier finding that HEV-specific T-cell responses are rather
weak in chronically infected solid organ transplant recipients
while much stronger T-cell responses can be observed in
immunocompetent patients with acute HEV genotype 3 infec-
tions.11 More and larger studies are required to better define
the importance of viral diversity for disease progression once
chronic hepatitis E infection has been established.
RBV displays antiviral activities against a broad range of RNA
and DNA viruses.26 Inhibition of HEV replication in vitro by
RBV has been shown to be mediated by a depletion of cellular
GTP pools.18 However, additional modes of actions of RBV
might be important as patients can develop chronic hepatitis E
even in the presence of mycophenolic acid, which also inhibits
IMPDH and thereby alters cellular GTP pools.6 We here suggest
that RBV-induced viral mutagenesis is important for HEV
therapy outcomes. Various in vitro studies showed that RBV
exhibits mutagenic properties against different viruses such as
GB virus B, poliovirus, Hantaan virus and foot-and-mouth
disease virus.27–30 Yet, few studies presented in vivo evidence
that RBV-induced mutagenesis is of relevance. The best studied
example is hepatitis C where partially contradicting results were
observed by direct sequencing of PCR products of about 30
clones per time point.31–34 However, deep sequencing of
patients being treated with RBV monotherapy revealed that,
even though no overall increase of nucleotide substitutions of
hepatitis C occurred during therapy, a mutagenic effect was
demonstrated with more frequent G-to-A and C-to-U nucleotide
transitions.35 We here demonstrate that RBV therapy is asso-
ciated with an increased HEV heterogeneity indicating that
nucleotide substitutions accumulate over time during treatment.
Of note, this diversity partially declined again in two patients
upon RBV therapy cessation, further supporting that RBV is
inducing HEV mutagenesis and that this effect is reversible.
Similar to the findings for HCV, we also observed an excess of
transitions compared with transversions in the HEV polymerase
and, in addition, we observed a surplus of synonymous versus
non-synonymous substitutions in the majority of the cases
(figures 1, 3 and 7).35 Nucleotide changes occurred throughout
the studied HEV regions in ORF1, ORF2 and ORF3 with no
preferential location of SNVs—which is also in line with find-
ings in hepatitis C where respective SNVs were not limited to
specific non-structural proteins as suggested previously but
occurred ubiquitously in the HCV genome.32 35 Overall, our
findings could indicate that the RBV-induced mutagenesis of
HEV may lead to an exceeding of a genomic error threshold
followed by lethal mutagenesis as it has been shown for other
viruses.19 Still, further studies in more patients are needed
which should try to determine correlations between viral
declines and RBV-induced viral diversity.
The HEV G1634R mutation was selected during RBV
therapy in two patients not achieving a sustained HEV clearance
and this mutant had a better replication capacity in vitro.17 We
here provide a more detailed analysis of how this variant
became dominant in the viral population over time.
Importantly, deep sequencing revealed that the G1634R mutant
was already present as a minor population before therapy in
patient #1 and the proportion gradually increased until treat-
ment month 11, when G1634R was the dominant strain repre-
senting more than two thirds of the HEV population (figure
4A). The mutant was also detectable before treatment in patient
#2, who failed to achieve a sustained virologic response (SVR),
and also in the third patient G1634R was the dominant strain
throughout follow-up. Overall, these data extend on our previ-
ous observation and suggest that the selection of G1634R may
have contributed to treatment failure. Next-generation sequen-
cing maybe used diagnostically to early identify patients at risk
for treatment failure who may require alternative treatment
approaches.
Importantly, next-generation sequencing revealed that the
situation might be even more complex, as various additional
amino acid changes were detected in some patients (figure 4).
These variants may have additional implications for the replica-
tion efficiency as demonstrated in figure 5. Viral constructs har-
bouring additional mutations in the ORF1 region next to the
G1634R mutation abrogated the improved replication fitness of
G1634R viruses and showed an increased RBV sensitivity. One
has to keep in mind that the p6 HEV clone is a cell culture
adapted isolate, which might not reflect the individual dominant
patient strain found in vivo in a given patient. Furthermore, due
to the limitations of Illumina sequencing, whereby no linkage
between polymorphisms can be assigned, we also performed a
linkage analysis via clonal sequencing methods, where single
viral amplicons are cloned into a vector and subsequently
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sequenced by standard Sanger sequencing. Here, we were able
to identify viral genomes harbouring all three SNVs in patient
#1. Although no genomes with all four SNVs for patient #2
and patient #4 were detected, different combinations with up
to three SNVs were also present in these populations.
The study has several strengths as this was the very first study
evaluating viral evolution over time in patients with chronic
hepatitis E by deep sequencing. We could study a cohort of
patients with and without sustained response to RBV treatment
and as single patients could be studied for up to nine different
time points. However, limitations need to be considered. Blood
sampling was performed in a routine clinical setting and
samples were retrospectively analysed based on availability. The
number of patients is still limited and a larger cohort needs to
be investigated. Moreover, different immunosuppressive regi-
mens were used in different patients and specific drugs may
interfere with viral RNA replication and thereby also affect the
viral population composition.36 37 Finally, the dose of RBV
varied between patients and was even adapted during treatment
based on tolerability, haemoglobin levels and kidney function.
Thus, drug exposure may have differed between individuals.
In summary, this first investigation of HEV intrahost evolution
revealed that viral diversity differs between patients but does
not show major intraindividual short-term variations in
untreated patients indicating that there is no major immune
selection pressure on HEV in immunocompromised patients
with chronic hepatitis E. Furthermore, we provide strong evi-
dence that RBV causes HEV mutagenesis in treated patients and
that an emergence of distinct viral populations may occur
during RBV therapy. Next-generation sequencing could be
useful to rapidly identify patients at risk for not achieving a sus-
tained virological response. Overall, this study gives novel
insights to better understand the pathophysiology of chronic
hepatitis E and may guide development of personalised antiviral
strategies.
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